|
|
CDK4/6抑制剂在消化道肿瘤中的研究进展
|
Abstract:
CDK4/6作为调节细胞周期的关键蛋白激酶，在衰老、DNA修复等行为中也扮演着重要的角色，对于CDK4/6以及其抑制剂的应用的相关研究也正在进行中，近年来成为在各种癌症类型中进行热点探究的潜在靶点。本文就CDK4/6抑制剂在消化道肿瘤治疗的研究进展进行讨论。
As a key protein kinase that regulates cell cycle, CDK4/6 also plays an important role in aging, DNA repair and other behaviors. Relevant studies on the application of CDK4/6 and its inhibitors are al-so in progress. In recent years, CDK4/6 has become a potential target for hot research in various cancer types. This article discusses the progress of CDK4/6 inhibitors in the treatment of digestive tract tumors.
| [1] | Sofie, N., Karoline, K. and Veronika, S. (2020) The Role of CDK6 in Cancer. International Journal of Cancer, 147, 2988-2995. https://doi.org/10.1002/ijc.33054 |
| [2] | Harbour, J.W., Luo, R.X., Dei Santi, A., et al. (1999) CDK Phosphorylation Triggers Sequential Intramolecular Interactions That Progressively Block Rb Functions as Cells Move through G1. Cell, 98, 859-869.
https://doi.org/10.1016/S0092-8674(00)81519-6 |
| [3] | Johnson, N. and Geoffrey, I.S. (2012) Cyclin-Dependent Kinase 4/6 Inhibition in Cancer Therapy. Cell Cycle, 11, 3913-3913. https://doi.org/10.4161/cc.22390 |
| [4] | Anne, F., Yan, G. and Piotr, S. (2022) CDK4 and CDK6 Kinases: From Basic Science to Cancer Therapy. Science, 375, eabc1495. https://doi.org/10.1126/science.abc1495 |
| [5] | Johannes, E. (2019) Management of Adverse Events Due to Cy-clin-Dependent Kinase 4/6 Inhibitors. Breast Care (Basel), 14, 86-92. https://doi.org/10.1159/000499534 |
| [6] | Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., et al. (2022) Overall Sur-vival with Ribociclib plus Letrozole in Advanced Breast Cancer. The New England Journal of Medicine, 386, 942-950. https://doi.org/10.1056/NEJMoa2114663 |
| [7] | Dickson, M.A., Schwartz, G.K., et al. (2016) Progression-Free Survival among Patients with Well-Differentiated or Dedifferentiated Liposarcoma Treated with CDK4 Inhibitor Palbo-ciclib: A Phase 2 Clinical Trial. JAMA Oncology, 2, 937-940. https://doi.org/10.1001/jamaoncol.2016.0264 |
| [8] | Assi, T., Kattan, J., Rassy, E., et al. (2020) Targeting CDK4 (Cyclin-Dependent Kinase) Amplification in Liposarcoma: A Comprehensive Review. Critical Reviews in Oncolo-gy/Hematology, 153, Article ID: 103029.
https://doi.org/10.1016/j.critrevonc.2020.103029 |
| [9] | Crozier, L., Foy, R., Mouery, B.L., et al. (2022) CDK4/6 In-hibitors Induce Replication Stress to Cause Long-Term Cell Cycle Withdrawal. EMBO Journal, 41, e108599. https://doi.org/10.15252/embj.2021108599 |
| [10] | Tong, J.S., Tan, X., Song, X.P., et al. (2022) CDK4/6 Inhibition Suppresses p73 Phosphorylation and Activates DR5 to Potentiate Chemotherapy and Immune Checkpoint Blockade. Cancer Research, 82, 1340-1352.
https://doi.org/10.1158/0008-5472.CAN-21-3062 |
| [11] | Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Can-cer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660 |
| [12] | Qian, Y., Wu, X., Wang, H.X., et al. (2020) PAK1 Silencing Is Synthetic Lethal with CDK4/6 Inhibition in Gastric Cancer Cells via Regulating PDK1 Expression. Human Cell, 33, 377-385. https://doi.org/10.1007/s13577-019-00317-6 |
| [13] | Bae, H.J., Kang, S.K., Kwon, W.S., et al. (2021) p16 Methyla-tion Is a Potential Predictive Marker for Abemaciclib Sensitivity in Gastric Cancer. Biochemical Pharmacology, 183, Ar-ticle ID: 114320.
https://doi.org/10.1016/j.bcp.2020.114320 |
| [14] | Chen, Z.H., Xu, Y.Y., Gong, J.F., et al. (2020) Pyrotinib Com-bined with CDK4/6 Inhibitor in HER2-Positive Metastatic Gastric Cancer: A Promising Strategy from AVATAR Mouse to Patients. Clinical and Translational Medicine, 10, e148. https://doi.org/10.1002/ctm2.148 |
| [15] | Bi, H.T., Shang, J., Zou, X., et al. (2021) Palbociclib Induces Cell Senescence and Apoptosis of Gastric Cancer Cells by Inhibiting the Notch Pathway. Oncology Letters, 22, 603. https://doi.org/10.3892/ol.2021.12864 |
| [16] | Min, A., Kim, J.E., Kim, Y.-J., et al. (2018) Cyclin E Overexpression Confers Resistance to the CDK4/6 Specific Inhibitor Palbociclib in Gastric Cancer Cells. Cancer Letters, 430, 123-132. https://doi.org/10.1016/j.canlet.2018.04.037 |
| [17] | Chen, L., et al. (2017) Dual Cyclin-Dependent Kinase 4/6 Inhibition by PD-0332991 Induces Apoptosis and Senescence in Oesophageal Squamous Cell Carcinoma Cells. British Journal of Pharmacology, 174, 2427-2443.
https://doi.org/10.1111/bph.13836 |
| [18] | Wang, J.Y., Li, Q.Q., Yuan, J.J., et al. (2017) CDK4/6 Inhibitor-SHR6390 Exerts Potent Antitumor Activity in Esophageal Squamous Cell Carcinoma by Inhibiting Phosphorylated Rb and Induc-ing G1 Cell Cycle Arrest. Journal of Translational Medicine, 15, 127. https://doi.org/10.1186/s12967-017-1231-7 |
| [19] | Karasic, T.B., O’Hara, M.H., Teitelbaum, U.R., et al. (2020) Phase II Trial of Palbociclib in Patients with Advanced Esophageal or Gastric Cancer. Oncologist, 25, e1864-e1868. https://doi.org/10.1634/theoncologist.2020-0681 |
| [20] | Zheng R., Zhang, S., Zeng, H., et al. (2022) Cancer Incidence and Mortality in China, 2016. Journal of the National Cancer Center, 2, 1-9. https://doi.org/10.1016/j.jncc.2022.02.002 |
| [21] | Thoma, O.M., Neurath, M.F. and Waldner, M.J. (2021) Cy-clin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment. Frontiers in Pharma-cology, 12, Article ID: 757120.
https://doi.org/10.3389/fphar.2021.757120 |
| [22] | Lee, M.S., Helms, T.L., Feng, N.P., et al. (2016) Efficacy of the Combination of MEK and CDK4/6 Inhibitors in Vitro and in Vivo in KRAS Mutant Colorectal Cancer Models. Oncotar-get, 7, 39595-39608.
https://doi.org/10.18632/oncotarget.9153 |
| [23] | Chen, S.-H., Gong, X., Zhang, Y., et al. (2018) RAF Inhibitor LY3009120 Sensitizes RAS or BRAF Mutant Cancer to CDK4/6 Inhibition by Abemaciclib via Superior Inhibition of Phospho-RB and Suppression of Cyclin D1. Oncogene, 37, 821-832. https://doi.org/10.1038/onc.2017.384 |
| [24] | Wang, Y.N., Liao, H.Y., Zheng, T.S., et al. (2020) Conditionally Re-programmed Colorectal Cancer Cells Combined with Mouse Avatars Identify Synergy between EGFR and MEK or CDK4/6 Inhibitors. American Journal of Cancer Research, 10, 249-262. |
| [25] | Piro, G., Carbone, C., Santoro, R., et al. (2018) Predictive Biomarkers for the Treatment of Resectable Esophageal and Esophago-Gastric Junction Adenocarci-noma: From Hypothesis Generation to Clinical Validation. Expert Review of Molecular Diagnostics, 18, 357-370. https://doi.org/10.1080/14737159.2018.1454312 |
